# BRUIN CLL-321 (NCT04666038)

> Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04666038
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Loxo Oncology, Inc.
- Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions: Pirtobrutinib; Idelalisib; Bendamustine; Rituximab
- Enrollment: 238
- Primary outcome: Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

## Commentary we found

- YouTube: 32
- Podcasts: 24
- X threads: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=bruin-cll-321-nct04666038

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04666038", "email": "<work email>"}; the inbox owner confirms by the emailed link.